Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cor Therapeutics Inc. (CORR) -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (338)	1/21/1999 4:32:00 PM
From: aknahow	Respond to of 712

While the market does not think the MTC event was positive for CORR, I think it was. My reasoning is the risk that Cor's new oral products will not work was always present. It did not change as result of MTC's decision. Now if after several years of trials an oral drug is brought to market, by Cor, that market will be a bit more robust. In addition, it would seem that Cor scientist, could learn, at least something from the decision of MTC. Perhaps additional issues or problems to address or even at worst, an earlier halt to development, saving resources are IMO an additional plus for CORR. Am well aware, the market, does not care what I think. <g>